KLRK1 and hepatocellular carcinoma: Induced IDO1 compromised MV-Edm-enhanced immune activation and antitumour efficacy of CD8+NKG2D+ cells, and the IDO1 inhibitor fludarabine, a drug known to decrease IDO1 expression32, achieved a more profound antitumour immune responses against HCC cells in vivo.